Research Analysts’ Weekly Ratings Updates for Travere Therapeutics (TVTX)

Posted by Alanna Baker on May 7th, 2026

Several analysts have recently updated their ratings and price targets for Travere Therapeutics (NASDAQ: TVTX):

5/6/2026 – Travere Therapeutics had its price target raised by Wells Fargo & Company from $40.00 to $50.00. They now have an “overweight” rating on the stock.
5/5/2026 – Travere Therapeutics had its price target raised by Wedbush from $53.00 to $55.00. They now have an “outperform” rating on the stock.
5/5/2026 – Travere Therapeutics had its price target raised by Citigroup Inc. from $53.00 to $59.00. They now have a “buy” rating on the stock.
5/5/2026 – Travere Therapeutics had its price target raised by HC Wainwright from $47.00 to $57.00. They now have a “buy” rating on the stock.
5/5/2026 – Travere Therapeutics had its price target raised by TD Cowen from $45.00 to $60.00. They now have a “buy” rating on the stock.
4/24/2026 – Travere Therapeutics had its price target raised by Guggenheim from $54.00 to $56.00. They now have a “buy” rating on the stock.
4/14/2026 – Travere Therapeutics had its price target raised by Citigroup Inc. from $48.00 to $53.00. They now have a “buy” rating on the stock.
4/14/2026 – Travere Therapeutics was upgraded by Piper Sandler from “neutral” to “overweight”. They now have a $49.00 price target on the stock.
4/14/2026 – Travere Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $47.00 to $56.00. They now have a “buy” rating on the stock.
4/14/2026 – Travere Therapeutics had its price target raised by Wedbush from $39.00 to $44.00. They now have an “outperform” rating on the stock.
4/14/2026 – Travere Therapeutics had its price target raised by Guggenheim from $49.00 to $54.00. They now have a “buy” rating on the stock.
4/14/2026 – Travere Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $47.00 price target on the stock.
3/25/2026 – Travere Therapeutics had its price target lowered by JPMorgan Chase & Co. from $44.00 to $41.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, insider Elizabeth E. Reed sold 44,715 shares of Travere Therapeutics stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $41.21, for a total value of $1,842,705.15. Following the transaction, the insider directly owned 111,996 shares of the company’s stock, valued at $4,615,355.16. The trade was a 28.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric M. Dube sold 64,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $41.09, for a total value of $2,629,760.00. Following the transaction, the chief executive officer owned 432,886 shares of the company’s stock, valued at approximately $17,787,285.74. This trade represents a 12.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 400,015 shares of company stock worth $15,895,428 in the last ninety days. 4.44% of the stock is owned by insiders.

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.